Akums Drugs and Pharmaceuticals Limited — Investor Meet, 13-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Akums reported robust Q1 FY27: revenue grew 13.9% to INR 1,167 Cr, and PAT surged 56.1% to INR 101 Cr. CDMO led growth (+18.6%) with strong volumes and higher API prices. Domestic branded revenue saw 7.3% growth, though margins were impacted by new hires. API losses narrowed, targeting breakeven this fiscal.

The company acquired Oriflame India's manufacturing, expanding into skin care and cosmetics. Management projects high-teen CDMO volume growth and sustained 14-15% EBITDA margins. Upcoming Zambia ($25M) and European orders are set to boost margins. Capacity expansion, including a new oral facility, is underway. With INR 1,616 Cr cash, Akums maintains a confident outlook for FY27, focusing on CDMO strength and strategic growth.